NEW YORK, Dec. 28, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ekso Bionics Holdings, Inc. ("Ekso" or the "Company") (NASDAQ: EKSO). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980.
The investigation concerns whether Ekso and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On December 14, 2017, Ekso advised investors that "the Company's internal control over financial reporting as of December 31, 2016 should no longer be relied upon and that a material weakness in the Company's internal control over financial reporting existed as of such date." On this news, Ekso's share price fell $0.15, or 6.17%, to close at $2.28 on December 15, 2017. On December 27, 2017, post-market, Ekso filed an amended annual report for 2016 and amended quarterly reports for the first three quarters of 2017. On this news, Ekso's share price has fallen sharply during intraday trading on December 28, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby
SOURCE Pomerantz LLP